Support Alert

Class 2 Medicines Recall: Co-amoxiclav 125 mg/31.25 mg/5 ml and 25 mg/62.5 mg/5 ml powder for oral suspension

The MHRA has issued a recall for two batches of Co-amoxiclav 125 mg/31.25 mg/5 ml and 25 mg/62.5 mg/5 ml powder for oral suspension from pharmacies. Sandoz Limited has notified the MHRA that this is a precautionary measure due to a potential packaging problem relating to poor seal adherence which could cause clumping of the powder within the bottle. A poor bottle seal could lead to degradation of the clavulanic acid within the powder and could potentially render the product ineffective.

Further information, affected batch details and actions to be taken can be found on the MHRA website.

Loading...

Renew for 2022

Your dedication to patient care has made us proud during 2021.

That's why you can count on us to represent your interests and support your efforts every step of the way in 2022.

RENEW YOUR MEMBERSHIP TODAY